Table 4.
Results of simple regression models among 71 patients with early RA with the concentration of Lp-PLA2 at T5 as the dependent variable.
| Lp-PLA2 at T5 | |||
|---|---|---|---|
| β | 95% CI | p value | |
| IMT T5 (n = 66) | 4.4/mm | −2.7; 11.5 | 0.22 |
| FMD T5 (n = 66) | −1.7/% | −3.8; 0.4 | 0.10 |
| Non-HDL-cholesterol T5 (n = 61) | 19.0/mmolL−1 | 10.5; 27.5 | 0.001 |
| HDL T5 (n = 61) | −31.8/mmolL−1 | −50.3; −13.3 | 0.001 |
| Cholesterol T5 (n = 61) | 11.5/mmolL−1 | 2.1; 20.8 | 0.02 |
| Ever smoking (n = 66) | 0.4/year | −0.3; 1.1 | 0.26 |
| BMI T5 (n = 66) | 2.5/unit | 0.3; 4.7 | 0.03 |
| SCORE T5 (n = 61) | 3.6/unit | −2.0; 9.2 | 0.21 |
| Reynolds Risk Score T5 (n = 39) | 2.8/unit | −0.2; 5.7 | 0.06 |
RA: rheumatoid arthritis; Lp-PLA2: lipoprotein-associated phospholipase A2; IMT: intima media thickness; FMD: flow mediated dilation; HDL: high-density lipoproteins; BMI: body mass index.